
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ixazomab is suitable for the treatment of multiple myeloma.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:332
It is mainly used for the treatment of chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and certain types of acute myeloid leukaemia (AML).【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:183
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:248
司帕生坦、Sparsentan、LuciSeta、Filspari、斯帕森坦【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:347
Suitable for treating severe alopecia areata in adults and adolescents aged 12 and above.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:254
Used for the treatment of advanced, unresectable cholangiocarcinoma with FGFR2 gene fusion or rearrangement.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:223
Treat RET gene fusion positive NSCLC and MTC.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:266
Treat non-small cell lung cancer, medullary thyroid carcinoma, and thyroid cancer caused by RET gene mutations.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:245
Enasidenib is suitable for Leukemia.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:264
Trametinib is a broad-spectrum anti-cancer drug.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:184
Patients with unresectable or metastatic melanoma with BRAF V600E mutation.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:207
Thrombocytopenia in patients with chronic liver disease and chronic immune disorders.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:291
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:8542025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:10562024-09-07
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended:3472026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:4202026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:6192026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:6062026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:4752026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended:6232026-31-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643